CooperSurgical Inc has signed an agreement to acquire Teva Pharmaceutical Industries Ltd's PARAGARD (intrauterine copper contraceptive) for $1.1bn in cash.

The deal will enable CooperSurgical to repay term loan debt and reinforce its central nervous system (CNS) in addition to its respiratory business areas.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CooperSurgical is a medical and surgical products provider based in the US, while Teva is an Israeli pharmaceutical company.

Chinese firm Basecare Medical Device Co Ltd has secured CNY100m ($15.34m) in a series B funding round.

The company plans to use the funds towards the development of third-generation test-tube baby technology.

See Also:

"The company plans to use the funds towards the development of third-generation test-tube baby technology."

SPR Therapeutics LLC has secured $25m in a series C venture funding round led by a family office and Frontcourt Ventures.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The US-based company plans to use the funds towards the commercialisation of its FDA-cleared SPRINT peripheral nerve stimulation (PNS) system and additional research.

Cheetah Medical Inc has secured an additional $11.76m in a series C funding round, bringing the total funding to $40.61m. The company previously raised $14.4m in an extended series C financing round in February.

The US-based firm intends to use the stocks towards the expansion of its business in the country.